L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
Skin hypopigmentation
- 10min
- May. 2022
- Supported by
Therapeutic classes inducing this adverse event
CTLA4 inhibitor, PD-1 inhibitor, Antiangiogenic agent, KIT inhibitor
CTCAE V5.0
Hypopigmentation or depigmentation covering <10% BSA no psychosocial impact
SIMPLIFIED GRADING
<10% BSA
Not obvious
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Hypopigmentation or depigmentation covering >10% BSA; associated psychosocial impact
SIMPLIFIED GRADING
>10% BSA OR Psychosocial impact
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events